Premium
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation
Author(s) -
Momota Hiroyuki,
Nariata Yoshitaka,
Miyakita Yasuji,
Hosono Ako,
Makimoto Atsushi,
Shibui Soichiro
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22542
Subject(s) - medicine , temozolomide , germline , lymphoblastic leukemia , anaplastic astrocytoma , germline mutation , oncology , cancer research , mutation , blood cancer , leukemia , glioblastoma , astrocytoma , cancer , genetics , gene , biology
We present a case of a 12‐year‐old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ). The patient had no family history of malignancy except her grand father and his siblings. Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment‐related acute leukemia have been reported after TMZ‐alone chemotherapy for malignant gliomas. We demonstrate a rare case of TMZ‐related ALL in a child with glioma possibly associated with a germline TP53 mutation. Pediatr Blood Cancer. 2010;55:577–579. © 2010 Wiley‐Liss, Inc.